Key result
DOACs linked to ~477% higher major bleeding risk than warfarin in Tetralogy of Fallot with AF.
Why the study?
Adults with complex congenital heart disease have a high prevalence of AF, but thromboembolic and bleeding risks and comparative bleeding outcomes between warfarin and DOACs needed evaluation.
Do direct oral anticoagulants (DOACs) increase major bleeding compared to warfarin in adults with Tetralogy of Fallot or pulmonary atresia with intact ventricular septum and atrial fibrillation?
Cohort (n=300)
Yes
Do direct oral anticoagulants (DOACs) increase major bleeding compared to warfarin in adults with Tetralogy of Fallot or pulmonary atresia with intact ventricular septum and atrial fibrillation?
Answers are grounded in this paper and cite their sources.
In adults with complex congenital heart disease (ToF and PA-IVS) and atrial arrhythmias, DOAC therapy is associated with a significantly higher risk of major bleeding compared to warfarin.
Background Adults with complex congenital heart disease (CHD), including tetralogy of Fallot (ToF) and pulmonary atresia with intact ventricular septum (PA-IVS), have a high prevalence of atrial fibrillation and flutter (AF). Objectives To evaluate thromboembolic and major bleeding risks in adults with ToF and PA-IVS and AF and compare bleeding outcomes between warfarin and direct oral anticoagulants (DOACs). Methods We conducted a retrospective cohort study of adults with Tetralogy of Fallot with pulmonary stenosis (TOF-PS), Tetralogy of Fallot with pulmonary atresia (TOF-PA), or PA-IVS treated for AF at Mayo Clinic sites from 1999 to 2023. Primary outcomes were thromboembolic events (stroke, transient ischemic attack, or systemic embolism) and major bleeding. Cox regression was used to identify clinical and echocardiographic predictors, controlling for age. Anticoagulant-associated bleeding was evaluated using multivariable Cox models. Results Among 300 patients (mean follow-up 7.9 years), 12 thromboembolic events occurred (5.23 per 1,000 person-years). CHA 2 DS 2 -VASc score predicted thromboembolism (c-statistic 0.78). Sixty-nine major bleeding events occurred (3.74 per 100 person-years). Bleeding risk was higher in ToF-PA than ToF-PS(HR 2.05; p=0.005) and in patients with prior Waterston shunts, RA pressure elevation, and RV dysfunction. DOAC use was associated with a higher bleeding risk compared with warfarin (adjusted HR 5.77; p<0.001). HAS-BLED demonstrated poor discrimination (c-statistic 0.59). Conclusions In adults with ToF and PA-IVS and AF, DOAC therapy was associated with substantially higher major bleeding risk than warfarin. CHA 2 DS 2 -VASc effectively predicted thromboembolism, whereas HAS-BLED performed poorly. Congenital- and right heart–specific factors should inform anticoagulation decisions in this high-risk population.
No takes yet. Share an insight, caveat, or question.
O’Shea et al. (2026) conducted a cohort in Tetralogy of Fallot and pulmonary atresia with intact ventricular septum and atrial fibrillation (n=300). Direct oral anticoagulants (DOACs) vs. Warfarin was evaluated on Major bleeding (adjusted HR 5.77, p=<0.001). In adults with Tetralogy of Fallot or pulmonary atresia and atrial fibrillation, DOAC therapy was associated with a higher major bleeding risk than warfarin.
Synapse has enriched 10 related papers. Consider them for comparative context: